Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

计划入组 105 人 · 首次发布于 2025 年 7 月 28 日

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

计划入组 30 人 · 首次发布于 2017 年 11 月 7 日

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

计划入组 85 人 · 首次发布于 2009 年 11 月 6 日

JAB-26766

PARP/MEK dual inhibitors (MD Anderson)

Ribose

C₅H₁₀O₅

POLY MEDICURE LIMITED

India

Poly Pharmaceuticals Inc

United States

ANHUI POLY PHARM.CO.,LTD.

China

IDEAYA Doses First Patient in Phase 1 Trial of IDE161 and Keytruda Combination for Endometrial Cancer

858 Therapeutics Receives FDA Fast Track Designation for PARG Inhibitor ETX-19477 in BRCA-Mutated Ovarian Cancer

FoRx Therapeutics Secures $50M Series A to Advance PARG Inhibitor for PARP-Resistant Cancers